UNSPSC 51263011: Terazosin hydrochloride anhydrous

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8QOP8Z9955. European Medicines Agency schedules terazosin hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04722MIG. Most nations, for tariff and trade purposes, schedule terazosin hydrochloride anhydrous under HS 29349990 and SITC 51579. As of Q4 2014, TERAZOSIN HYDROCHLORIDE ANHYDROUS remains US FDA's Preferred Term for this commodity.

Terazosin hydrochloride anhydrous bears US NLM identifiers UMLS ID C2241271 and NCI Concept Code C75056. SMILES: COC1CC2C(CC1OC)NC(NC2N)N3CCN(CC3)C(=O)C4CCCO4.CL.

UNSPSC 51263011 Terazosin hydrochloride anhydrous is a Commodity code that nominally identifies a specific pharmaceutical compound, but recent state and local solicitations tagged with this code show little alignment with the code's pharmaceutical scope. The Seminole County, Florida opportunity (IFB 60459723LAS) seeks naloxone and drug deactivation systems for community health initiatives, not terazosin. The Texas Health and Human Services Commission RFI (HHS0017013) solicits vendor capabilities for direct-to-manufacturer prescription programs across multiple drug categories, not a single active pharmaceutical ingredient. State and local procurement offices appear to be using this code as a broad pharmaceutical-procurement tag rather than a specific-drug classifier, which suggests either downstream taxonomy inconsistency or repurposing of the code for general pharmacy procurement signaling. The code shows activity from state health agencies and county health departments, though the recent opportunities diverge substantially from the code's nominal definition.

The geographic spread reflects activity in Florida and Texas, with Texas showing preliminary market-intelligence activity through an RFI phase that precedes formal competitive solicitation. Seminole County's IFB (response deadline July 26, 2023, though posted June 30, 2026) is structured as a fixed-fee, unit-priced procurement with quarterly deliveries, a two-year initial term plus one-year renewal option, and compliance requirements including E-Verify and drug-free workplace certification. The Texas RFI is an exploratory phase designed to inform future formal RFP development around direct-to-manufacturer contracting models and value-based pricing without rebates. Neither opportunity specifies set-aside or disadvantaged-enterprise designations. The code's recent activity is sparse and materially misaligned with its nominal scope, limiting its utility as a purchasing signal for firms seeking pharmaceutical-ingredient opportunities.